carbamates has been researched along with Local Neoplasm Recurrence in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC)." | 7.81 | Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. ( Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y, 2015) |
| "The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC)." | 3.81 | Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. ( Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y, 2015) |
| "The recurrent hepatocellular carcinoma enlarged quite rapidly and induced multiple peritoneal disseminations and lung metastases." | 1.56 | Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report. ( Arai, J; Fukumura, Y; Imai, M; Kato, J; Kojima, K; Kondo, M; Kurokawa, K; Mori, M; Ohki, T; Seki, M; Shibata, C; Tagawa, K; Takagi, K; Toda, N, 2020) |
| " Details of serious adverse events (SAEs) were recorded." | 1.46 | Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. ( Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Kurokawa, K | 1 |
| Ohki, T | 1 |
| Kato, J | 1 |
| Fukumura, Y | 1 |
| Imai, M | 1 |
| Shibata, C | 1 |
| Arai, J | 1 |
| Kondo, M | 1 |
| Takagi, K | 1 |
| Kojima, K | 1 |
| Seki, M | 1 |
| Mori, M | 1 |
| Toda, N | 1 |
| Tagawa, K | 1 |
| Tholander, B | 1 |
| Koliadi, A | 1 |
| Botling, J | 1 |
| Dahlstrand, H | 1 |
| Von Heideman, A | 1 |
| Ahlström, H | 1 |
| Öberg, K | 1 |
| Ullenhag, GJ | 1 |
| Warburton, L | 1 |
| Meniawy, TM | 1 |
| Calapre, L | 1 |
| Pereira, M | 1 |
| McEvoy, A | 1 |
| Ziman, M | 1 |
| Gray, ES | 1 |
| Millward, M | 1 |
| Cullen, GD | 1 |
| Finnes, HD | 1 |
| Markovic, SN | 1 |
| Volcheck, GW | 1 |
| Shimizu, H | 1 |
| Matsui, K | 1 |
| Iwabuchi, S | 1 |
| Fujikawa, T | 1 |
| Nagata, M | 1 |
| Takatsuka, K | 1 |
| Tanemura, H | 1 |
| Nakazaki, H | 1 |
| Nakano, M | 1 |
| Watanabe, T | 1 |
| Ida, H | 1 |
| Hagiwara, S | 1 |
| Kono, M | 1 |
| Minami, T | 1 |
| Chishina, H | 1 |
| Arizumi, T | 1 |
| Takita, M | 1 |
| Yada, N | 1 |
| Minami, Y | 1 |
| Ueshima, K | 1 |
| Nishida, N | 1 |
| Kudo, M | 2 |
| Hassany, M | 1 |
| Elsharkawy, A | 1 |
| Maged, A | 1 |
| Mehrez, M | 1 |
| Asem, N | 1 |
| Gomaa, A | 1 |
| Mostafa, Z | 1 |
| Abbas, B | 1 |
| Soliman, M | 1 |
| Esmat, G | 1 |
| Preda, CM | 1 |
| Baicus, C | 1 |
| Sandra, I | 1 |
| Oproiu, A | 1 |
| Manuc, T | 1 |
| Constantinescu, I | 1 |
| Gavrila, D | 1 |
| Diculescu, M | 1 |
| Dumitru, R | 1 |
| Vasilescu, C | 1 |
| Tieranu, C | 1 |
| Istratescu, D | 1 |
| Voiosu, T | 1 |
| Manuc, M | 1 |
| Sugimoto, K | 1 |
| Kim, SR | 1 |
| Kim, SK | 1 |
| Imoto, S | 1 |
| Tohyama, M | 1 |
| Kim, KI | 1 |
| Ohtani, A | 1 |
| Hatae, T | 1 |
| Yano, Y | 1 |
| Hayashi, Y | 1 |
| Vanhaecke, C | 1 |
| Deilhes, F | 1 |
| Chanal, J | 1 |
| Regnier-Rosencher, E | 1 |
| Boitier, F | 1 |
| Boulinguez, S | 1 |
| Avril, MF | 1 |
| Guégan, S | 1 |
| Dupin, N | 1 |
| Aractingi, S | 1 |
| Meyer, N | 1 |
| Kramkimel, N | 1 |
| Calleja, JL | 1 |
| Crespo, J | 1 |
| Rincón, D | 1 |
| Ruiz-Antorán, B | 1 |
| Fernandez, I | 1 |
| Perelló, C | 1 |
| Gea, F | 1 |
| Lens, S | 1 |
| García-Samaniego, J | 1 |
| Sacristán, B | 1 |
| García-Eliz, M | 1 |
| Llerena, S | 1 |
| Pascasio, JM | 1 |
| Turnes, J | 1 |
| Torras, X | 1 |
| Morillas, RM | 1 |
| Llaneras, J | 1 |
| Serra, MA | 1 |
| Diago, M | 1 |
| Rodriguez, CF | 1 |
| Ampuero, J | 1 |
| Jorquera, F | 1 |
| Simon, MA | 1 |
| Arenas, J | 1 |
| Navascues, CA | 1 |
| Bañares, R | 1 |
| Muñoz, R | 1 |
| Albillos, A | 1 |
| Mariño, Z | 1 |
| Kunschner, LJ | 1 |
| Fine, H | 1 |
| Hess, K | 1 |
| Jaeckle, K | 1 |
| Kyritsis, AP | 1 |
| Yung, WK | 1 |
| McClelland, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC[NCT02771405] | Phase 3 | 150 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for carbamates and Local Neoplasm Recurrence
| Article | Year |
|---|---|
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glio | 2002 |
12 other studies available for carbamates and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Fatal Outcome; Hepacivirus; Hepatitis | 2020 |
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystade | 2020 |
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma.
Topics: Adult; Aged; Carbamates; Circulating Tumor DNA; Disease Progression; Female; Humans; Imidazoles; Mal | 2020 |
Successful encorafenib desensitization in a patient with recurrent metastatic melanoma.
Topics: Aged; Carbamates; Female; Humans; Melanoma; Neoplasm Recurrence, Local; Skin Neoplasms; Sulfonamides | 2021 |
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.
Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; | 2017 |
Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatoc | 2017 |
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Fem | 2018 |
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembol | 2019 |
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatoc | 2015 |
BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.
Topics: Adult; Antineoplastic Agents; Carbamates; Drug Substitution; Humans; Imidazoles; Indoles; Melanoma; | 2017 |
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbama | 2017 |
Chemotherapy in reticulum-cell sarcoma in five dogs and a cat and in mast-cell leukemia in a cat.
Topics: Animals; Antineoplastic Agents; Azirines; Carbamates; Cat Diseases; Cats; Cyclophosphamide; Dog Dise | 1971 |